Anti-rhGAA antibody formation in Chinese Pompe disease infants underwent enzyme replacement therapy
スポンサーリンク
概要
- 論文の詳細を見る
- 2010-07-30
著者
-
Chiang Shu-chuan
Department Of Medical Genetics College Of Medicine National Taiwan University
-
Hwu Wuh-liang
Department Of Medical Genetics And Pediatrics National Taiwan University Hospital
-
CHIEN Yin-Hsiu
Department of Medical Genetics, National Taiwan University Hospital
-
HWU Wuh-Liang
Department of Medical Genetics, National Taiwan University Hospital
-
CHIEN Yin-Hsiu
Department of Medical Genetics and Pediatrics, National Taiwan University Hospital
-
CHIANG Shu-Chuan
Department of Medical Genetics, National Taiwan University Hospital
-
LEE Ni-Chung
Department of Medical Genetics and Pediatrics, National Taiwan University Hospital
-
LEE Ni-Chung
Department of Medical Genetics, National Taiwan University Hospital
関連論文
- Rapid detection of FGFR3 gene mutation in achondroplasia by DHPLC system-coupling heteroduplex and fluorescence-enhanced primer-extension analysis
- The controversy regarding diagnostic criteria for early myoclonic encephalopathy
- Spectrum of hypermethioninemia in Taiwan
- Changing outcome in inborn errors after newborn screening
- Phenotypes and genotypes of hyperphenylalaninemia in Taiwan
- Phenotypes and genotypes of hyperphenylalaninemia in Taiwan
- Glucose-6-phosphatase gene mutations in Taiwan Chinese patients with glycogen storage disease type Ia
- Hyperammonemia and positive allopurinol test in hyperinsulinism-hyperammonemia syndrome : Taiwanese case report
- Spectrum of hypermethioninemia in Taiwan
- Changing outcome in inborn errors after newborn screening
- The Impact of Tandem Mass Technology on the Management of Inborn Errors in Taiwan
- Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer
- The Impact of Tandem Mass Technology on the Management of Inborn Errors in Taiwan
- Anti-rhGAA antibody formation in Chinese Pompe disease infants underwent enzyme replacement therapy
- Second tier tests in newborn screening
- Novel heterozygous tissue-nonspecific alkaline phosphatase (TNAP) gene mutations causing lethal perinatal hypophosphatasia